Last updated: February 21, 2026
What is NDC 33342-0288?
NDC 33342-0288 refers to Zirabev (bevacizumab-bvzr), a biosimilar, approved by the FDA on February 21, 2020. Zirabev is a biosimilar to Avastin (bevacizumab), used in oncology treatments for various cancers, including colorectal, lung, glioblastoma, and kidney cancers.
Market Context
The bevacizumab market, primarily occupied by Avastin, has generated approximately $7.5 billion globally in 2021, with the United States accounting for nearly 80% of sales. Biosimilars like Zirabev entered this market to offer lower-cost alternatives and increase access.
Market Size and Penetration
| Market Segment |
2021 Revenue |
Market Share (Estimated, 2023) |
Comments |
| Avastin (branded) |
$6.0 billion |
80% |
Dominant biologic in indications |
| Zirabev (biosimilar) |
<$500 million |
10% (projected) |
Growing uptake in US, EU markets |
| Other biosimilars |
<$200 million |
10% |
Limited market presence |
Zirabev's market share is expected to grow based on biosimilar acceptance trends, especially amid price competition and policy incentives. The biosimilar market adoption rate varies by region but remains slower in the U.S. compared to Europe. In Europe, biosimilar penetration has reached upwards of 70% for similar drugs.
Price Projections
Current Pricing Landscape
| Product |
Estimated Price per Vial |
Price Difference (vs. Avastin) |
Notes |
| Avastin (branded) |
$1,200 – $1,500 |
— |
Last price update, depending on indication |
| Zirabev (biosimilar) |
$600 – $900 |
30-50% lower than Avastin |
Discounted price varies by payer, region, and volume |
Price Trajectory (2023-2027)
- 2023: Biosimilar remains at approximately 50% discount to Avastin, driven by payer negotiations and volume discounts.
- 2024-2025: Price reductions expected of 10-15%, contingent on increased biosimilar uptake.
- 2026-2027: Price stabilization at approximately 50% discount, volume growth may reduce prices further marginally.
Key Factors Affecting Price
- Payer policies: Shift toward favoring biosimilar prescribing to reduce costs.
- Regulatory environment: US policies can influence biosimilar market share.
- Manufacturing costs: Biosimilar production typically less expensive than originators, allowing sustained lower pricing.
- Market competition: Entry of additional biosimilars could further drive prices down.
Regulatory and Commercial Dynamics
- The FDA approved Zirabev as a biosimilar to Avastin, meeting requirements under the BPCIA pathway.
- Launch strategies include aggressive pricing, rebates, and discounts.
- Patent litigation and exclusivity periods influence market entry timelines. Avastin's primary patents expired in 2018, but secondary patents and data exclusivity may extend generic/biosimilar entry.
Competitive Landscape
| Biosimilar |
Approval Date |
Market Share (estimated, 2023) |
Key Differentiators |
| Zirabev (bevacizumab-bvzr) |
2020 |
10% |
First FDA-approved biosimilar to Avastin |
| Beovu (conbercept) |
2020 |
Limited |
Different therapeutic class |
| Other entrants |
2022-2023 |
Emerging |
Multiple biosimilars in pipeline |
Key Opportunities and Risks
-
Opportunities
- Expanding use in multiple oncology indications.
- Price competition leading to increased volume sales.
- Favorable payer policies supporting biosimilar adoption.
-
Risks
- Slow uptake due to physician and patient hesitance.
- Patent litigation delaying market penetration.
- Competition from new biosimilars or interchangeable biologics.
Price Outlook Summary
| Year |
Projected Average Price per Vial |
Expected Market Share (%) |
Revenue Estimate (USD) |
| 2023 |
$700 |
10% |
~$200 million |
| 2024 |
$675 |
15% |
~$250 million |
| 2025 |
$650 |
20% |
~$300 million |
| 2026 |
$625 |
25% |
~$350 million |
| 2027 |
$600 |
30% |
~$400 million |
(All projections assume steady growth in biosimilar acceptance and pricing stability.)
Key Takeaways
- Zirabev is positioned as a key biosimilar in the oncology market, targeting a large established incumbent (Avastin).
- Biosimilar pricing is expected to stabilize around 50-60% of branded biologic prices, with incremental decreases over the next 4 years.
- Market penetration likely to grow, driven by cost containment policies, with US adoption remaining second to Europe.
- Competition from additional biosimilars and potential interchangeable biologics will influence long-term pricing.
- Volume growth remains a primary driver for revenue expansion, more than price reductions alone.
FAQs
Q1: What factors influence biosimilar price reductions?
Payer negotiations, market competition, manufacturing efficiencies, and regional regulations primarily dictate biosimilar pricing.
Q2: How does regional regulation affect growth?
European markets tend to adopt biosimilars faster due to earlier approval processes and prescriber acceptance, while US uptake is slower due to patent protections and prescribing habits.
Q3: When are more biosimilars expected to enter the market?
Additional biosimilars are expected to launch from 2023 through 2025, potentially increasing competition and lowering prices.
Q4: How significant is payer policy in driving biosimilar adoption?
Very; policies incentivize biosimilar use through formulary preferences, rebates, and step therapy measures.
Q5: What are the main risks to revenue growth for Zirabev?
Delayed market entry due to patent litigation, slow prescriber adoption, and the emergence of new biosimilars or interchangeable biologics.
References
[1] IQVIA Institute. (2022). The Global Use of Medicines in 2021. IQVIA.
[2] FDA. (2020). Approval Letter for Zirabev. U.S. Food & Drug Administration.
[3] Novartis. (2022). Market launch and biosimilar adoption strategies. Novartis Reports.
[4] Sager, J., & Gee, D. (2022). Biosimilar market trends. Journal of Pharmaceutical Innovation, 17(4), 420-435.
[5] US Food & Drug Administration. (2021). Biosimilar Development and Approval Process. FDA Guidelines.
